MERCK - Vorapaxar: Subgroup Analyses Hold the Key: TRA-2P study Met Primary Endpoint
Merck today announced the topline results from much awaited Vorapaxar clinical study in secondary prevention of heart attack and stroke (TRA-2P). Addition of Vorapaxar to standard of care significantly reduced the risk of the protocol- specified primary endpoint of the composite of cardiovascular death, MI, stroke or urgent coronary revascularization compared to SoC. Lower risk of Intracranial hemorrhage was observed with the patients without the history of previous stroke. The full data is planned to present at the American College of Cardiology Scientific Sessions in March 2012. In addition, Company is expected to review the clinical data from TRACER and TRA-2P with external experts to help better understand the profile of Vorapaxar in specific patient populations.
COMPANIES MENTIONED
MERCK
MERCK
